HALO News and Press, Halozyme Therapeutics Inc.

2024-07-31 08:51:19 ET More on J&J, Genmab, Halozyme, etc. 4 Positives For Johnson & Johnson Johnson & Johnson: Seriously Undervalued At Peak Pessimism Johnson & Johnson Q2: Robust New Product Pipeline Most U.S. pharmas don't pay any U.S. inco...

2024-07-26 05:15:00 ET Summary With inflation slowing in many countries, equity markets saw modest returns in Q2. Stocks in emerging markets and North America performed particularly well. The portfolio came up short against its benchmark, the MSCI AC World Index, this quarter. ...

Halozyme to Report Second Quarter 2024 Financial and Operating Results PR Newswire SAN DIEGO , July 23, 2024 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced it will release its second quarter 2024 financial and operating re...

2024-07-22 03:26:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

2024-07-19 07:32:00 ET Summary Laughing Water Capital is a concentrated, long biased investment partnership open to accredited investors. Our interests are fully aligned with our partners as nearly all of our personal wealth is invested in our strategy. For Q2 2024, Class A intere...

2024-07-05 06:20:00 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips The healthcare sector continues to be a hotbed of innovation, with biotechnology leading the charge. From groundbreaking gene therapies to next-generation cancer treatments, biotech companies...

2024-07-01 10:02:13 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips With the technology sector taking over in 2024, now is a great time to consider the best breakout biotech stocks to buy. Investing in these companies can be risky yet extremely rewarding, w...

2024-06-25 06:36:05 ET More on Halozyme Therapeutics Halozyme Therapeutics: The Story Brightens Halozyme Therapeutics, Inc. (HALO) Q1 2024 Earnings Call Transcript Halozyme Therapeutics, Inc. 2024 Q1 - Results - Earnings Call Presentation Bristol Myers Opdivo...

Halozyme Announces Roche's OCREVUS® SC with ENHANZE® Receives European Commission Approval for Relapsing and Primary Progressive Multiple Sclerosis PR Newswire OCREVUS ® subcutaneous (SC) injection offers a new 10-minute administration with comparable effica...

Halozyme Announces argenx Receives FDA Approval for VYVGART® Hytrulo Co-Formulated with ENHANZE® for Chronic Inflammatory Demyelinating Polyneuropathy PR Newswire VYVGART® Hytrulo is the first and only neonatal Fc receptor (FcRn) blocker that is delivered as...